Revisionary analysis without meaning change (or, could women be analytically oppressed?)

This chapter develops a conception of philosophical analysis which makes sense of the idea that a correct analysis can be revisionary (in that it departs from ordinary or expert belief and linguistic usage). The view is superior to the alternatives defended by most proponents of ‘conceptual ethics’ and ‘conceptual engineering’ (according to which revisionary theorizing involves replacing words or concepts) because it better explains the arguments we advance when we engage with proposed revisionary analyses. A key idea is that analytic claims can emerge in the course of debate without change of meaning, so that our acceptance (perhaps late in the debate) of some analyticity can fix the meaning of a word as we used it all along. The discussion focuses on Haslanger’s revisionary analysis of gender.Publisher PD

A puzzle about accommodation and truth

Open access funding provided by Umea University.The purpose of this paper is to present and discuss a puzzle involving accommodation. The puzzle is based on three assumptions. The first assumption is that accommodation takes place after an utterance. The second assumption is that accommodation can make a difference to the truth-value of an utterance even if the utterance is not about the future. The third assumption is that something that takes place after an utterance cannot make a difference to the truth-value of the utterance unless the utterance is about the future. Since these assumptions are jointly inconsistent, one of them must be false. The question is which one we ought to reject. The majority of the discussion is devoted to discussing each of the options, and the tentative conclusion is that the most plausible strategy is to reject the third thesis. That amounts to saying that something that takes place after an utterance can make a difference to the truth-value of the utterance even if the utterance is not about the future.Publisher PDFPeer reviewe

What are we doing when we theorise about context sensitivity?

Postprin

Scepticism about moral superiority

Chapman & Huffman suggest that we might change people’s behavior toward animals by resisting an argument that because humans are intellectually superior to animals they are also morally superior to animals. C & H try to show that the premise is false: Humans are not intellectually superior. Several commentators have resisted this response. We suggest that there are other ways of attacking the argument: The notion of moral superiority on which the argument relies is dubious, and the obvious ways of reformulating the argument are instances of the “naturalistic fallacy.”Publisher PDFNon peer reviewe

Knowing without knowing : implicit cognition and the minds of infants and animals

The main aim of this paper is to highlight the need to address the conceptual problem of “implicit knowledge” or “implicit cognition” —a notion especially important in the study of the nonverbal minds of animals and infants. We review some uses of the term ‘implicit’ in psychology and allied disciplines,and conclude that conceptual clarification of this notion is not only lacking, but largely avoided and reduced to a methodological problem. We propose that this elusive notion is central in the study not only of animal and infant minds, but also the human adult mind. Some promising approaches in developmental and evolutionary psychology towards innovative conceptualisation of implicit knowledge remain conceptually underdeveloped and in need of reconsideration and re-elaboration. We conclude by suggesting that the challenge of implicit cognition and nonverbal minds will only be solved through a concerted interdisciplinary approach between psychology and other disciplines.Publisher PDFPeer reviewe

Capuchin monkeys individuate objects based on spatio-temporal and property/kind information : evidence from looking and reaching measures

This paper is an output of the project ‘Rethinking Mind and Meaning: A case study from a co-disciplinary approach’ (Award Nr.: AH/ L015234/1), funded by the Arts and Humanities Research Council (AHRC), as part of the Science in Culture Theme (http://www.sciculture.ac.uk).A core component of any folk physical understanding of the world is object individuation - the cognitive ability to parse sensory input into discrete objects. Whereas younger human infants use spatio-temporal information to individuate objects, they do not use property and kind information until one year of age. Some researchers propose that object individuation based on property/kind information depends on language acquisition and sortal concepts. However, there is evidence that preverbal infants and nonhuman animals also use both types of information. The present study aimed to further explore the evolutionary origins of object individuation by testing a new-world monkey species, capuchin monkeys (Sapajus spp.), using both manual search (n = 29) and looking time (n = 23) measures. In Spatio-temporal trials, subjects saw one or two objects dropped into a box, but always found (or saw) only one. In Property/kind trials, subjects saw either object A or B being dropped into a box and then always found (or saw) object A. The capuchin monkeys looked longer and searched more on inconsistent trials – with outcome differing in quantity or in kind - which suggested that they had expectations based on both spatio-temporal and property-kind representations. Looking time and search measures gave convergent results at the group but not at the individual level. Our results add to the existing evidence contradicting the linguistic hypothesis of property/kind individuation. However, contrary to recent discussions, we argue that these and related results can be explained without appealing to the notion of sortal concepts or multiple representational systems, and suggest that a full picture of the ontogeny and phylogeny of object individuation requires further empirical and theoretical research.Publisher PDFPeer reviewe

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1. METHODS We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12. RESULTS In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease. CONCLUSIONS In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.

Global dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G are suggestive of a selective advantage but may also be due to a random founder effect. We investigate the hypothesis for positive selection of spike D614G in the United Kingdom using more than 25,000 whole genome SARS-CoV-2 sequences. Despite the availability of a large dataset, well represented by both spike 614 variants, not all approaches showed a conclusive signal of positive selection. Population genetic analysis indicates that 614G increases in frequency relative to 614D in a manner consistent with a selective advantage. We do not find any indication that patients infected with the spike 614G variant have higher COVID-19 mortality or clinical severity, but 614G is associated with higher viral load and younger age of patients. Significant differences in growth and size of 614G phylogenetic clusters indicate a need for continued study of this variant

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention